Home|New Products||||||Technical support|

Ki67 - HS-398 117

A marker protein for proliferating cells
Monoclonal rat purified IgG
Cat. No.: HS-398 117
Amount: 200 µl
Price: 415.00 €
Cat. No. HS-398 117  200 µl purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C until use.
Applications ICC: 1 : 500
IHC: 1 : 200 (see remarks) gallery  
IHC-P/FFPE: 1 : 100 gallery  
Clone 311H2
Subtype IgG2b (λ light chain)
Immunogen Synthetic peptide corresponding to AA 1234 to 1252 from mouse Ki67 (UniProt Id: E9PVX6)
Epitop Epitop: AA 1234 to 1252 from mouse Ki67 (UniProt Id: E9PVX6)
Reactivity Reacts with: mouse (E9PVX6).
No signal: human (P46013), rat (D4A0Y6).
Other species not tested yet.
Specificity Specific for Ki 67
Remarks

IHC: Heat-mediated antigen retrieval (in citrate buffer pH 6) is required for immunohistochemical stainings

Data sheet hs-398_117_.pdf
Cat. No.: HS-398 117
Quantity: 200 µl
Price: 415.00 €

Species-specific detection of proliferation antigen-Ki67 in murine but not human FFPE spleen

Background

Expression of the nuclear protein Ki 67 is strictly associated with cell proliferation and preferentially expressed during the late G1, S, G2 and M phases of the cell cycle. Resting cells (G0 phase) lack Ki 67 expression .
Immunohistochemical detection of Ki 67 is a simple and reproducible method to determine the tumour proliferative index and is a predictive and prognostic biomarker in certain types of human cancer, such as breast cancer, gastric cancer or prostate cancer. Moreover, higher Ki 67 scores may be associated with increased tumor sensitivity to radiation therapy and chemotherapy.
In preclinical and clinical studies Ki 67 expression is used as a pharmacodynamic biomarker. Absence of a decrease in Ki 67 early in treatment might be predictive of therapeutic failure.

Protocols